French company Dassault Systemes agreed to buy Medidata Solutions Inc. (NASDAQ: MDSO) for $5.8 billion. The all-cash transaction was approved by the boards of directors of both companies and is expected to close during the last quarter of 2019.
The purchase price of $92.25 per share is at a slight discount to Medidata’s Tuesday closing price of $94.75. For its most recent quarter, Medidata had reported a 16% growth in revenue to nearly $174 million along with adjusted EPS of $0.45. The company has a market valuation of $5.9 billion.
Medidata provides data and analytics tools for clinics and medical device companies and Dassault hopes to expand its footprint in the fast-growing life sciences market with the help of this acquisition.
Bernard Charles, CEO, Dassault Systemes said, “Medidata’s leading position in clinical trials complements our life sciences solutions on the 3DEXPERIENCE collaborative platform. Medidata’s recent expansion into real world evidence and analytics coupled with the power of modeling and simulation demonstrates how the virtual world will catalyse the next generation of patient-inclusive therapeutics.”
Medidata’s shares have gained 44% thus far this year. The stock was down 3.2% in morning hours on Wednesday.
Most Popular
United Parcel Service (UPS) seems on track to regain lost strength
Cargo giant United Parcel Service, Inc. (NYSE: UPS) ended fiscal 2023 on a weak note, reporting lower revenues and profit for the fourth quarter. The company experienced a slowdown post-pandemic
IPO Alert: What to look for when Boundless Bio goes public
Boundless Bio is preparing to debut on the Nasdaq stock market this week, and become the latest addition to the list of biotech firms that have launched IPOs this year.
Nike (NKE) bets on innovation and partnerships to return to high growth
Sneaker giant Nike, Inc. (NYSE: NKE) has been going through a rough patch for some time, with sales coming under pressure from weak demand and rising competition. Post-pandemic, the company